Upgrade to SI Premium - Free Trial

Form 4 Stoke Therapeutics, Inc. For: Jul 16 Filed by: Harrison Seth Loring

July 17, 2026 4:37 PM
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Harrison Seth Loring
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 28.8 07/16/2026 G (1) 29,555 (2) 09/09/2029 Common Stock 29,555 $ 0 0 D
Stock Option (Right to Buy) $ 28.8 07/16/2026 G (1) 29,555 (2) 09/09/2029 Common Stock 29,555 $ 0 29,555 I By Trust (3)
Stock Option (Right to Buy) $ 26.53 07/16/2026 G (1) 14,777 (4) 06/02/2030 Common Stock 14,777 $ 0 0 D
Stock Option (Right to Buy) $ 26.53 07/16/2026 G (1) 14,777 (4) 06/02/2030 Common Stock 14,777 $ 0 14,777 I By Trust (3)
Stock Option (Right to Buy) $ 40.37 07/16/2026 G (1) 11,650 (5) 06/07/2031 Common Stock 11,650 $ 0 0 D
Stock Option (Right to Buy) $ 40.37 07/16/2026 G (1) 11,650 (5) 06/07/2031 Common Stock 11,650 $ 0 11,650 I By Trust (3)
Stock Option (Right to Buy) $ 12.96 07/16/2026 G (1) 21,000 (6) 06/06/2032 Common Stock 21,000 $ 0 0 D
Stock Option (Right to Buy) $ 12.96 07/16/2026 G (1) 21,000 (6) 06/06/2032 Common Stock 21,000 $ 0 21,000 I By Trust (3)
Stock Option (Right to Buy) $ 12.46 07/16/2026 G (1) 19,441 (7) 06/12/2033 Common Stock 19,441 $ 0 0 D
Stock Option (Right to Buy) $ 12.46 07/16/2026 G (1) 19,441 (7) 06/12/2033 Common Stock 19,441 $ 0 19,441 I By Trust (3)
Stock Option (Right to Buy) $ 16.41 07/16/2026 G (1) 7,639 (8) 06/04/2034 Common Stock 7,639 $ 0 0 D
Stock Option (Right to Buy) $ 16.41 07/16/2026 G (1) 7,639 (8) 06/04/2034 Common Stock 7,639 $ 0 7,639 I By Trust (3)
Stock Option (Right to Buy) $ 10.9 07/16/2026 G (1) 29,747 (9) 06/02/2035 Common Stock 29,747 $ 0 0 D
Stock Option (Right to Buy) $ 10.9 07/16/2026 G (1) 29,747 (9) 06/02/2035 Common Stock 29,747 $ 0 29,747 I By Trust (3)
Stock Option (Right to Buy) $ 29.46 07/16/2026 G (1) 17,786 (10) 06/02/2036 Common Stock 17,786 $ 0 0 D
Stock Option (Right to Buy) $ 29.46 07/16/2026 G (1) 17,786 (10) 06/02/2036 Common Stock 17,786 $ 0 17,786 I By Trust (3)
Explanation of Responses:
1. The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
2. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
3. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
4. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
5. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
6. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
7. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
8. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
9. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.
10. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
/s/ Jonathan Allan, Attorney-in-Fact 07/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings